Endovascular thrombectomy (EVT) does not lead to better outcomes at 90 days compared with usual care or best medical ...

Safety outcomes included good functional outcome (modified Rankin Scale (mRS) score of 0–2 at last follow-up), procedure-related morbidity (permanent neurological deficits), procedure-related ...

Grace Therapeutics (GRCE) announced that its Phase 3 STRIVE-ON safety trial met its primary endpoint and provides evidence of clinical benefit ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery ...

Revalesio updates new analyses from phase 2 RESCUE clinical study of RNS60 in patients with acute ischemic stroke: Tacoma, Washington Friday, February 7, 2025, 18:00 Hrs [IST] Rev ...

MIND was a prospective, open-label trial that enrolled adults up to 80 years old with moderate-large (20-80 mL) ...

treatment with REC-994 400 mg showed promising signals in both MRI-based lesion volume reduction and functional outcome as ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to placebo, treatment with REC-994 400 mg showed promi ...

University of Cincinnati experts will present research at the International Stroke Conference 2025 in Los Angeles.